RU2020102237A - Связывающие il-1-бета антитела для применения в лечении рака - Google Patents
Связывающие il-1-бета антитела для применения в лечении рака Download PDFInfo
- Publication number
- RU2020102237A RU2020102237A RU2020102237A RU2020102237A RU2020102237A RU 2020102237 A RU2020102237 A RU 2020102237A RU 2020102237 A RU2020102237 A RU 2020102237A RU 2020102237 A RU2020102237 A RU 2020102237A RU 2020102237 A RU2020102237 A RU 2020102237A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- use according
- paragraphs
- functional fragment
- therapeutic agents
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 18
- 201000011510 cancer Diseases 0.000 title claims 18
- 238000011282 treatment Methods 0.000 title claims 14
- 239000011230 binding agent Substances 0.000 title claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 27
- 239000002246 antineoplastic agent Substances 0.000 claims 25
- 239000003814 drug Substances 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 25
- 229940124597 therapeutic agent Drugs 0.000 claims 25
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 14
- 206010061218 Inflammation Diseases 0.000 claims 13
- 230000004054 inflammatory process Effects 0.000 claims 13
- 206010009944 Colon cancer Diseases 0.000 claims 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 12
- 229960001838 canakinumab Drugs 0.000 claims 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 11
- 108010074051 C-Reactive Protein Proteins 0.000 claims 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 9
- 201000005202 lung cancer Diseases 0.000 claims 9
- 208000020816 lung neoplasm Diseases 0.000 claims 9
- 229950003717 gevokizumab Drugs 0.000 claims 8
- 229960003301 nivolumab Drugs 0.000 claims 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 6
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 5
- 201000004101 esophageal cancer Diseases 0.000 claims 5
- 238000011272 standard treatment Methods 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 102100032752 C-reactive protein Human genes 0.000 claims 4
- 239000012270 PD-1 inhibitor Substances 0.000 claims 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims 4
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 4
- 229960003852 atezolizumab Drugs 0.000 claims 4
- 229950002916 avelumab Drugs 0.000 claims 4
- 229950009791 durvalumab Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 4
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 4
- 229960002621 pembrolizumab Drugs 0.000 claims 4
- 229950007213 spartalizumab Drugs 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 229960005386 ipilimumab Drugs 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- 239000012829 chemotherapy agent Substances 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229960002633 ramucirumab Drugs 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 108010081667 aflibercept Proteins 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 229960002760 ziv-aflibercept Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/836—Intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/868—Vaccine for a specifically defined cancer kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523458P | 2017-06-22 | 2017-06-22 | |
| US62/523,458 | 2017-06-22 | ||
| US201762529515P | 2017-07-07 | 2017-07-07 | |
| US62/529,515 | 2017-07-07 | ||
| US201762550325P | 2017-08-25 | 2017-08-25 | |
| US201762550307P | 2017-08-25 | 2017-08-25 | |
| US62/550,307 | 2017-08-25 | ||
| US62/550,325 | 2017-08-25 | ||
| US201762596054P | 2017-12-07 | 2017-12-07 | |
| US62/596,054 | 2017-12-07 | ||
| US201862649631P | 2018-03-29 | 2018-03-29 | |
| US62/649,631 | 2018-03-29 | ||
| IBPCT/IB2018/053096 | 2018-05-03 | ||
| US15/970,542 US20190048072A1 (en) | 2017-06-22 | 2018-05-03 | USE OF IL-1beta BINDING ANTIBODIES |
| TW107115136 | 2018-05-03 | ||
| US15/970,542 | 2018-05-03 | ||
| TW107115136A TW201904993A (zh) | 2017-06-22 | 2018-05-03 | IL-1β 結合抗體之用途 |
| PCT/IB2018/053096 WO2018234879A1 (en) | 2017-06-22 | 2018-05-03 | Il-1beta binding antibodies for use in treating cancer |
| PCT/IB2018/054637 WO2018235056A1 (en) | 2017-06-22 | 2018-06-22 | Il-1beta binding antibodies for use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020102237A true RU2020102237A (ru) | 2021-07-22 |
| RU2020102237A3 RU2020102237A3 (OSRAM) | 2022-03-11 |
Family
ID=62530267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020102237A RU2020102237A (ru) | 2017-06-22 | 2018-06-22 | Связывающие il-1-бета антитела для применения в лечении рака |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20190048072A1 (OSRAM) |
| EP (1) | EP3642234A1 (OSRAM) |
| JP (4) | JP2020524694A (OSRAM) |
| KR (2) | KR20200019865A (OSRAM) |
| CN (1) | CN110831967A (OSRAM) |
| AU (4) | AU2018287519B2 (OSRAM) |
| BR (1) | BR112019027558A2 (OSRAM) |
| CA (2) | CA3061874A1 (OSRAM) |
| CL (1) | CL2019003799A1 (OSRAM) |
| CO (1) | CO2019014433A2 (OSRAM) |
| IL (1) | IL271221A (OSRAM) |
| JO (1) | JOP20190292A1 (OSRAM) |
| MX (1) | MX2019015516A (OSRAM) |
| PH (1) | PH12019502857A1 (OSRAM) |
| RU (1) | RU2020102237A (OSRAM) |
| SG (1) | SG11201911283UA (OSRAM) |
| TW (3) | TW201904993A (OSRAM) |
| WO (1) | WO2018234879A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60583B1 (sr) | 2012-02-13 | 2020-08-31 | Agency Science Tech & Res | Ljudska monoklonalna antitela koja vrše neutralizaciju il-ss |
| AU2018287519B2 (en) * | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
| CN112584857A (zh) * | 2018-05-09 | 2021-03-30 | 诺华股份有限公司 | 卡那吉努单抗的用途 |
| WO2020128620A1 (en) * | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1beta binding antibodies |
| CA3135838A1 (en) * | 2019-04-01 | 2020-10-08 | Immetas Therapeutics, Inc. | Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein |
| CA3142662A1 (en) * | 2019-06-06 | 2020-12-10 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
| US20210009674A1 (en) * | 2019-07-09 | 2021-01-14 | Tavotek Biotherapeutics (Hong Kong) Limited | Bispecific antibodies to tnf-alpha and il-1beta and uses thereof |
| JPWO2021182573A1 (OSRAM) * | 2020-03-12 | 2021-09-16 | ||
| RU2745814C1 (ru) * | 2020-06-05 | 2021-04-01 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция левилимаба и ее применение |
| EP3970727A1 (en) * | 2020-09-16 | 2022-03-23 | Johann Wolfgang Goethe-Universität Frankfurt | Means for reducing radiotherapy resistance and adverse effects |
| WO2022091375A1 (ja) * | 2020-10-30 | 2022-05-05 | 国立研究開発法人国立循環器病研究センター | 周産期心筋症治療剤 |
| WO2022167916A1 (en) * | 2021-02-03 | 2022-08-11 | Novartis Ag | Use of il-1b binding antibodies for treating neuroinflammatory disorders |
| WO2023038619A1 (en) * | 2021-09-08 | 2023-03-16 | Board Of Regents, The University Of Texas System | USE OF IL-1β BINDING ANTIBODIES |
| CN115125303B (zh) * | 2022-06-07 | 2023-02-24 | 北京大学第一医院 | 阿帕替尼药敏标记物及其相关试剂的应用 |
| CN116139268A (zh) * | 2023-03-13 | 2023-05-23 | 上海交通大学医学院附属仁济医院 | 靶向IL-1β的抗体在制备治疗去势抵抗型前列腺癌中的用途 |
| CN116688130A (zh) * | 2023-06-08 | 2023-09-05 | 桂林医学院附属医院 | 靶向IL-1β/IL-1R1通路的拮抗剂在抑制肝癌肺转移前微环境或肺转移的药物中的应用 |
| WO2024258943A1 (en) * | 2023-06-13 | 2024-12-19 | Merck Sharp & Dohme Llc | Methods of using cyclic peptides for trapping interleukin-1 beta |
| WO2025235276A1 (en) * | 2024-05-06 | 2025-11-13 | Icahn School Of Medicine At Mount Sinai | Combination of il-1 receptor inhibitors, anti pd-1, and il-4 inhibitors in the treatment of cancer |
| WO2025242806A1 (en) | 2024-05-23 | 2025-11-27 | Universität Duisburg-Essen | A METHOD FOR PREDICTING THE RESPONSE OF A PATIENT WITH DLBCL TO ANTI-IL-1ß THERAPY |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| ES2335232T3 (es) | 2005-06-21 | 2010-03-23 | Xoma Technology Ltd. | Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta. |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| TWI424147B (zh) | 2005-07-04 | 2014-01-21 | 尼康美景股份有限公司 | Distance measuring device |
| NZ569541A (en) | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP2388266B1 (en) | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US20090258020A1 (en) * | 2008-01-07 | 2009-10-15 | Patrys Limited | Antibody designated barb3, barb3 related antibodies, and methods of making and using same |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| KR101846590B1 (ko) | 2010-06-11 | 2018-04-09 | 교와 핫꼬 기린 가부시키가이샤 | 항 ｔｉｍ-3 항체 |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP6097702B2 (ja) | 2011-03-03 | 2017-03-15 | アペクシジェン， インコーポレイテッド | 抗ｉｌ−６受容体抗体およびその使用方法 |
| WO2012121679A1 (en) * | 2011-03-09 | 2012-09-13 | Agency For Science, Technology And Research | Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| RS60583B1 (sr) * | 2012-02-13 | 2020-08-31 | Agency Science Tech & Res | Ljudska monoklonalna antitela koja vrše neutralizaciju il-ss |
| KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2014022758A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| KR101947702B1 (ko) | 2012-10-04 | 2019-02-14 | 다나-파버 캔서 인스티튜트 인크. | 인간 단클론 항-pd-l1 항체 및 사용 방법 |
| JP6359019B2 (ja) | 2012-10-24 | 2018-07-18 | ノバルティス アーゲー | ＩＬ−１５Ｒα型、ＩＬ−１５Ｒα型を発現する細胞、ならびにＩＬ−１５ＲαおよびＩＬ−１５／ＩＬ−１５Ｒα複合体の治療上の使用 |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| HUE049957T2 (hu) | 2013-03-15 | 2020-11-30 | Glaxosmithkline Ip Dev Ltd | Lag-3 elleni kötõfehérjék |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| SG11201601844TA (en) | 2013-09-13 | 2016-04-28 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| WO2015081158A1 (en) | 2013-11-26 | 2015-06-04 | Bristol-Myers Squibb Company | Method of treating hiv by disrupting pd-1/pd-l1 signaling |
| WO2015083120A1 (en) * | 2013-12-04 | 2015-06-11 | Novartis Ag | USE OF IL-1β BINDING ANTIBODIES |
| SG11201604738TA (en) | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| CA3193936A1 (en) | 2014-01-15 | 2015-07-23 | Kadmon Corporation, Llc | Immunomodulatory agents |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| HRP20212033T1 (hr) | 2014-01-28 | 2022-04-01 | Bristol-Myers Squibb Company | Anti-lag-3 antitijela za liječenje hematoloških maligniteta |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
| PL3148579T3 (pl) | 2014-05-28 | 2021-07-19 | Agenus Inc. | Przeciwciała anty-gitr i sposoby ich zastosowania |
| DK3149042T3 (da) | 2014-05-29 | 2019-11-04 | Spring Bioscience Corp | PD-L1-antistoffer og anvendelser deraf |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| WO2015195163A1 (en) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Pd-l1 antagonist fully human antibody |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EP3206711B1 (en) | 2014-10-14 | 2023-05-31 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| DK3215532T3 (da) | 2014-11-06 | 2020-01-02 | Hoffmann La Roche | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| AR103867A1 (es) | 2015-03-06 | 2017-06-07 | Sorrento Therapeutics Inc | Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos |
| US10508149B2 (en) | 2015-04-01 | 2019-12-17 | Anaptysbio, Inc. | Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) |
| AU2016261770B2 (en) * | 2015-05-12 | 2022-06-02 | Drexel University | Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same |
| MX2017015260A (es) | 2015-06-03 | 2018-02-19 | Squibb Bristol Myers Co | Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer. |
| RU2753439C2 (ru) | 2015-07-23 | 2021-08-16 | Инхибркс, Инк. | Поливалетные и полиспецифичные gitr-связывающие слитые белки |
| CN114272371A (zh) * | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3334758A1 (en) | 2015-08-12 | 2018-06-20 | Medimmune Limited | Gitrl fusion proteins and uses thereof |
| AU2018287519B2 (en) * | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
-
2018
- 2018-05-03 AU AU2018287519A patent/AU2018287519B2/en not_active Ceased
- 2018-05-03 CA CA3061874A patent/CA3061874A1/en active Pending
- 2018-05-03 JP JP2019570897A patent/JP2020524694A/ja not_active Withdrawn
- 2018-05-03 US US15/970,542 patent/US20190048072A1/en not_active Abandoned
- 2018-05-03 WO PCT/IB2018/053096 patent/WO2018234879A1/en not_active Ceased
- 2018-05-03 TW TW107115136A patent/TW201904993A/zh unknown
- 2018-05-03 KR KR1020197035726A patent/KR20200019865A/ko not_active Ceased
- 2018-06-22 MX MX2019015516A patent/MX2019015516A/es unknown
- 2018-06-22 KR KR1020207001676A patent/KR20200021086A/ko not_active Ceased
- 2018-06-22 JP JP2019571038A patent/JP2020524698A/ja not_active Withdrawn
- 2018-06-22 US US16/624,130 patent/US20230220063A1/en not_active Abandoned
- 2018-06-22 TW TW107121619A patent/TW201904995A/zh unknown
- 2018-06-22 TW TW112108903A patent/TW202400641A/zh unknown
- 2018-06-22 AU AU2018288060A patent/AU2018288060B2/en not_active Ceased
- 2018-06-22 RU RU2020102237A patent/RU2020102237A/ru unknown
- 2018-06-22 EP EP18749503.1A patent/EP3642234A1/en not_active Withdrawn
- 2018-06-22 PH PH1/2019/502857A patent/PH12019502857A1/en unknown
- 2018-06-22 CA CA3066045A patent/CA3066045A1/en active Pending
- 2018-06-22 SG SG11201911283UA patent/SG11201911283UA/en unknown
- 2018-06-22 BR BR112019027558-4A patent/BR112019027558A2/pt not_active Application Discontinuation
- 2018-06-22 CN CN201880041546.8A patent/CN110831967A/zh active Pending
- 2018-12-22 JO JOP/2019/0292A patent/JOP20190292A1/ar unknown
-
2019
- 2019-12-05 IL IL271221A patent/IL271221A/en unknown
- 2019-12-19 CO CONC2019/0014433A patent/CO2019014433A2/es unknown
- 2019-12-20 CL CL2019003799A patent/CL2019003799A1/es unknown
-
2021
- 2021-10-07 AU AU2021245184A patent/AU2021245184A1/en not_active Abandoned
- 2021-10-19 AU AU2021254559A patent/AU2021254559A1/en not_active Abandoned
-
2022
- 2022-01-10 US US17/572,228 patent/US20220389090A1/en not_active Abandoned
- 2022-09-15 JP JP2022146790A patent/JP2022181214A/ja active Pending
-
2023
- 2023-02-01 JP JP2023014125A patent/JP2023071657A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020102237A (ru) | Связывающие il-1-бета антитела для применения в лечении рака | |
| Gao et al. | Anti-VEGF/VEGFR2 monoclonal antibodies and their combinations with PD-1/PD-L1 inhibitors in clinic | |
| Hirano et al. | Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy | |
| Brosnan et al. | Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies | |
| Singh et al. | Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer | |
| JP2020524694A5 (OSRAM) | ||
| Park et al. | Chemotherapy for advanced gastric cancer: review and update of current practices | |
| Pinto et al. | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) | |
| Tsubamoto et al. | Combination chemotherapy with itraconazole for treating metastatic pancreatic cancer in the second-line or additional setting | |
| Morishita et al. | Targeting receptor tyrosine kinases in gastric cancer | |
| Pessi et al. | Targeted therapy-induced diarrhea: a review of the literature | |
| JP2020524698A5 (OSRAM) | ||
| Xu et al. | Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review | |
| Izzedine et al. | Adverse kidney effects of epidermal growth factor receptor inhibitors | |
| Liang et al. | A pilot study of apatinib as third-line treatment in patients with heavily treated metastatic colorectal cancer | |
| Yamamoto et al. | Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors | |
| Desai et al. | Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers | |
| Sievers et al. | The multidisciplinary management of colorectal cancer: present and future paradigms | |
| Jomrich et al. | Targeted therapy in gastric cancer | |
| Renouf et al. | A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer | |
| Satolli et al. | Gastric cancer: The times they are a-changin’ | |
| Turgeman et al. | Evolving treatment paradigms in esophageal cancer | |
| Peng et al. | Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC | |
| Singh | Role of molecular targeted therapeutic drugs in treatment of breast cancer: A review article | |
| Armstrong et al. | Molecular Profiling in Metastatic Colorectal Cancer. |